Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by Wide Margin; Guides FY23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance
March 1, 2023 4:05 PM ESTStrong Execution Drove Record Revenues in 2022 of $3.7 billion, an increase of 18% over 2021Positioned for Total Revenue and Net Income Growth in 2023 Â Xywav Enters 2023 as the Oxybate Therapy of Choice and Company's Largest Product by Net SalesEnhanced Investment in R&D to Advance Pipeline towards Key Value Inflection Points in 2023 and 2024Company is Well-Positioned to Achieve Vision 2025
DUBLIN, March 1, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the... More
